【Abstract】 Fibroblast growth factor23 (FGF23) is one kind of osteogenic hormone that can adjust the metabolism of phosphor and 1,25(OH)2D. FGF23 combines with fibroblast growth factor receptors 1 (FGFR1) by coordinating with coreceptor Klotho and maintains serum phosphor within normal limits by increasing renal excretion of phosphor. Besides, FGF23 can reduce synthesis of 1,25(OH)2D and promotes its degradation to reduce intestinal absorption of phosphor.Moreover, FGF23 can reduce synthesis and secretion of parathyroid hormone, (PTH) by affecting parathyroid glands. Before serum phosphor increasing, serum FGF23 increases obviously and serum Klotho reduces significantly with the reduction of renal function in chronic kidney disease (CKD).Current research shows that FGF23/Klotho axis is firm related with disorders of calcium and phosphorus metabolism, secondary hyperparathyroidism (SHPT) and cardiovascular diseases (CVD) in the development of CKD.FGF23/Klotho axis may play a key role in the development of chronic kidney diseasemineral and bone disorder (CKDMBD).Further study on the relationship between FGF23/Klotho axis and CKD provides a new visual angle for CKDMBD diagnosis and treatment. This article reviews the research status and the development of FGF23/Klotho axis and CKD.